The HbA1c testing devices market reached approximately USD 1.82 billion in 2026. The growth is primarily driven by the increasing incidence of diabetes, high demand for point-of-care diagnostics, and changing regulatory environments. This report benefits major stakeholders involved in the entire value chain, including medical device manufacturers, CROs, software & data integration vendors, and distributors.
